Skip to main content
Premium Trial:

Request an Annual Quote

Avecia and TriLink to Integrate Technology

This article has been updated from a previous version to include additional information about the partnership.

NEW YORK, Feb. 27 (GenomeWeb News) - Avecia and TriLink announced today they will adopt common technology to offer customers "seamless" scale-up in oligo development and manufacturing.

 

Avecia is a GMP oligo manufacturer based in Millford, Mass., while TriLink, based in San Diego, is a custom oligonucleotide manufacturer with a focus on the discovery and pre-clinical stages of drug discovery.

 

The companies said that the alliance will speed the manufacture of oligos for drug discovery, development, and commercialization, and will offer an option for drugmakers "looking to minimize the challenges and risks associated with transitioning from a research-grade vendor to an oligonucleotide development service and manufacturing company."

 

Benefits of the common technology platform include "regulatory simplicity, cost control, time savings and risk minimization," the companies said.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.